| Name | Title | Contact Details |
|---|
NCD Corporation is a Eastlake, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy. Today, our attention is on the development and commercialization of patented thin-film, cortical electrode technology for intracranial electroencephalography (iEEG) and depth electrodes for stereoelectroencephalography (sEEG) recording of brain activity. The products currently available in these categories have significant limitations such as low recording resolution and high risk of infection. NeuroOne believes our technology can address these unmet needs upon initial commercialization with pipeline technology to advance the field by enabling minimally invasive techniques and all-in-one diagnostic and therapeutic options. While our initial focus is Epilepsy, future applications in Parkinson`s disease, Essential tremors, and Dystonia are within sight. NeuroOne technologies will be presented to a well-defined market, eager for the advancement they bring. There are 188 hospital centers licensed to perform epilepsy surgical procedures in the U.S. The current addressable market opportunity for is approximately $525.6 million. As more patients choose the minimally invasive procedures made available by NeuroOne technology, the future opportunity is estimated to be approximately $14.9 billion with full market penetration.
Optics Inc is a Brunswick, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Acutus Medical is committed to pioneering a breakthrough technology to optimize the treatment strategies for complex cardiac arrhythmias by developing innovative, safe, efficacious, and cost-effective solutions for individuals suffering from these complex cardiac arrhythmias. Our mission is to develop and market a platform technology of safe, cost-effective and clinically advanced tools for the minimally invasive diagnosis (mapping) of complex arrhythmias (Atrial Fibrillation and Ventricular Tachycardia) that enable Physicians to optimize treatments and expand the ablation/therapeutic markets. In the pursuit of our mission, we will conduct all of our activities with the highest integrity and strive to become the world’s most valued company within the markets we serve to patients, customers, colleagues, investors, business partners, employees, and the communities in which we work and live.
Henry Schein, Inc. is the world`s largest provider of health care products and services to office-based dental, animal health and medical practitioners. The Company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500® Company and a member of the S&P 500® and NASDAQ 100® Indexes, Henry Schein employs more than 21,000 Team Schein Members and serves more than one million customers. The Company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items. The Company also offers its customers exclusive, innovative technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services. Headquartered in Melville, N.Y., Henry Schein has operations or affiliates in 32 countries. The Company`s sales reached a record $11.6 billion in 2016, and have grown at a compound annual rate of approximately 15 percent since Henry Schein became a public company in 1995